Viral Vector Market is Expected to Reach USD 1,564.4 Mn by 2027

Global Viral Vector Market is witnessing a high CAGR growth of 20% and is expected to reach USD 1,564.4 Mn by 2027.

The global viral vector market is growing significantly due to increasing number of clinical studies related to the genomics and growing potential applications in novel drug delivery approaches. Moreover, expansion of healthcare and research infrastructure and growing burden of cancer diseases aare expected to thrive the growth of viral vector industry. In addition, rising demand for site specific drug delivery is expected to boost the growth of viral vector industry during the forecast period.

Viral vector gene therapies are one of most booming fields in the science.  However, only four in vivo viral-vector therapies are available in the market and ~100 gene therapies are in clinical trials phase with rigorous development in preclinical phase. Multinational pharmaceutical companies have diverted their focus on the potential of viral vectors along with developing acquisitions with more than 7 biotech-companies that valued above USD 1.0 Bn from last two years and is expected to increase more during the forecast period.

Moreover, the global sales of viral vector gene therapies are forecasted to elevate with the rate of ~50% with in next-five years which would have huge impact on the lives of more than 10,000 patients. Upcoming viral vector-based gene therapies are expected to pull the market for the development of innovative therapies.

Covid-19 pandemic has effectively impacted the growth of viral vector industry. Viral vector has played a significant role in development of covid-19 vaccine. Major pharmaceutical and biopharmaceutical companies are focused on the development of vector-based vaccine to meet the demand for growing covid infection crisis across the globe which uplifted the growth of viral vector industry and gained focus of companies for the development of viral vector-based therapies.

Global Viral Vector Market by Region Outlook (Revenue, USD Million, 2021-2027)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Based on region, Asia-Pacific is expected to witness remarkable growth during the forecast period due to growing research activities and an increase in viral vector product launches for novel gene therapy in China, India, and Mexico.

 The Global Viral Vector Market Segmentation:

Global Viral Vector Market by Type Outlook (Revenue, USD Million, 2021-2027)

• Adenoviral Vectors
• Lentiviral Vectors
• Retroviral Vectors
• Adeno-Associated Viral Vectors
• Others

Global Viral Vector Market by Disease Type Outlook (Revenue, USD Million, 2021-2027)

• Genetic Disorders
• Infectious Diseases
• Cancer
• Others

Global Viral Vector Market by Application Type Outlook (Revenue, USD Million, 2021-2027)

• Basic Research
• Vaccinology
• Gene Therapy

Key Findings:

• Based on type, adenoviral vector is expected to dominate the market during the forecast period due to rise in prevalence for diseases such as pneumonia, diarrhoea, bronchitis, and viral influenza
• Based on diseases, genetic disorders segment held the largest market share in 2020 due to presence of high incidence and availability of viral vectors for the treatment of genetic diseases across the world
• Based on applications, vaccinology segment is expected to dominate the market in 2021-2027 due to expanding application of viral vectors in vaccine development
• Based on region, North America dominated the growth of market in 2020 and expected to maintain same dominance during forecast period

Company Profiles and Competitive Intelligence

The key players operating in the Viral Vector market are

• Lonza
• Merck
• Oxford BioMedica
• CGT Catapult
• Cobra Biologics
• uniQure
• FUJIFILM Diosynth Biotechnologies
• Spark Therapeutics
• Batavia Biosciences B.V.
• BioNTech IMFS GmbH
• FinVector Oy
• Genelux Corporation
• Kaneka Eurogentec S.A.
• Lonza Group AG
• MaxCyte, Inc
• Sirion-Biotech GmbH Spark Therapeutics, Inc.
• Thermo Fisher Scientific Inc.
• Vector Biolabs
• Vigene Biosciences, Inc.
• Virovek, Inc

Recent News:

• In April 2020, Merck and MiliporeSigma collectively spent USD 110.0 Mn to open new viral vector facility at California. This was spent for the development of viral vector contract manufacturing facilities for gene therapy. This expansion helped to double the production capacity to support industrialization and commercialization of viral vectors.
• In July 2021, Berkeley Lights announced strategic collaboration with Thermo Fisher Scientific that aimed to address challenges in commercial-scale viral vector development and manufacturing. This collaboration is expected to bring Berkeley’s leadership in functional biologics with Thermo Fishers expertise in viral vector analytics and manufacturing. This would gear up the development of stable LA and AAV producer cell lines.